T. S. WILSONt M.B., B.CH., M.R.C.P.I. Brit. med. J'., 1965, 2, [904] [905] [906] [907] [908] Authoritative teaching on the management of chronic bronchitis stresses the importance of giving antibacterial agents for acute exacerbations (Crofton, 1963 ; Garrod, Scadding, and Watson, 1963) . But Johnston (1963) reviewed the clinical evidence of the nine controlled clinical trials of treatment of exacerbations of bronchitis which had been carried out up to that time and found that definite evidence of benefit was shown in only one trial. In his opinion the evidence in favour of the long-term prophylactic use of antibiotics was more definite than that in favour of the therapeutic use for acute illnesses.
The pathogenic organisms which are considered important (May, 1958) are Haemophilus influenzae and Streptococcus pneumoniae. These are often found in the sputum during acute exacerbations, and the sputum usually becomes purulent (Elmes and White, 1953) . There is histological evidence (Lynne Reid, 1958 ) that bacterial invasion during acute exacerbations causes the permanent damage to the lung. However, antibiotics given between exacerbations produce no immediate benefit even when the sputum is purulent, although the same " pathogenic " bacteria are often found in the sputum (Elmes, Knox, and Fletcher, 1953) . The routine use of antibiotics in the management of patients with acute exacerbations of bronchitis admitted to hospital gives rise to the danger of cross-infection by antibiotic-resistant organisms. Shortly before the trial reported here was started there was an outbreak of staphylococcal cross-infection, which made it necessary to withhold conventional antibiotic treatment in chronic bronchitic patients with acute exacerbations. These patients seemed to respond as rapidly as patients receiving antibiotics. With a disease so variable as chronic bronchitis the value of a particular treatment is difficult to assess, and therefore a formal double-blind trial for sequential analysis was planned and is reported here. The comparison was between the use of ampicillin, a broad-spectrum antibiotic, and no antibiotic.
Methods

Selection of Patients
Patients admitted to hospital for acute exacerbations of chronic bronchitis were accepted to the trial if they gave at least a three-year history of productive cough for more than three months in the year, and a history of at least two illnesses with increased sputum during that time. Patients with the following conditions were not accepted: severe cardiac failure unrelated to their chest disease ; carcinoma of the lung; lung abscess; long-standing bronchiectasis; evidence of disseminated infection or septicaemia ; active tuberculosis ; allergy to penicillin. Also patients on adrenal corticoid treatment were not accepted. Cases of "cor pulmonale" were accepted. Previous antibiotic treatment, apart from a history of allergy, was ignored.
Grading and Pairing
Patients were graded according to the clinical evidence of bacterial infection. Those who showed two or more of the following were placed into the more severe grade I: (a) fever of over 99.5°F. (37.5°C.), (b) pulmonary consolidation, and (c) purulent sputum. The rest were placed in the less severe grade II.
Patients were paired and given a trial number. To be paired together two patients had to be (a) admitted within two weeks of each other, (b) within 15 years of the same age, (c) of the same grade (I or II), and (d) of the same sex. When there were alternative patients available for pairing at any one time the closest match was used.
Treatment
All patients were given similar treatment, apart from the capsules of antibiotic or placebo. This treatment included bed rest only if the patients were unable to get out of bed. Bronchodilator drugs were given orally and by aerosol. Cardiac and respiratory failure were treated with digitalis, diuretics, oxygen, and respiratory stimulants when necessary. Postural coughing and deep-breathing exercises were performed three or four times a day, and when they tolerated it the patients were encouraged to sleep with the foot of the bed raised and without pillows.
All patients received capsules of identical appearance which contained either ampicillin or an inert sugar. Boxes containing a week's supply of capsules were prepared by the hospital pharmacist; each box had a number corresponding to that allocated to the patient when admitted to the trial. The statistician had arranged with the pharmacist in advance which member of each pair was to receive ampicillin and which placebo. Neither the ward staff nor the assessing doctors had access to this information until the trial had been completed. The capsules were administered so that the patients on ampicillin received 1 g. six-hourly for three days and 0.5 g. six-hourly for four days. (Wright and McKerrow, 1959) , and a specimen of sputum was sent for culture. The following were recorded daily: (1) four-hourly temperature, pulse, and respiration rate; (2) daily sputum volume and appearance; and (3) changes in clinical signs. Repeat peak flow recordings were done by the same observer every other day. Sputum was sent for culture on the fifth and seventh days.
The assessments of which of each pair responded more satisfactorily to treatment were not made until all the information on both patients could be assembled. The assessments were made at day 7, when the course of capsules ended ; again on the day of discharge; and, finally, when followed up between 6 and 18 months after discharge.
Withdrawals
Any patient who deteriorated clinically after admission or who failed to improve after three days was regarded as a treatment failure, compared with his pair, and given any treatment necessary. If deterioration was due to allergy to penicillin or increasing bronchospasm requiring corticoid therapy he was not regarded as a treatment failure but was replaced if possible by the next suitable patient. Patients for whom suitably matched pairs could not be found in two weeks were withdrawn from the trial.
Statistical Analysis
Using only the data recorded on the forms during the first seven days, two of us made a decision on which member of each pair responded better to treatment. Assessments were also made at the end of the hospital stay and at the end of the follow-up period. These results were entered in the sequential analysis diagram prepared by the statistician (see Chart). In this diagram the limits are defined by the usual probability limits-namely, that a result would only be considered significant if its chance probability was less than 1: 20 (P<0.05). The other limits of the diagram were defined as follows: for a result to be of clinical value benefit must be manifest in seven cases for every three in which the treatment is unsuccessful (9I=0.7. 0=0.3).
Conventional statistical methods were used for the analysis of single criteria of response and the importance of such factors as the presence of pathogenic organisms on admission. x2 test was applied when the numbers were sufficient; in other instances the exact probability test was used. Again, the criterion of significance was a chance probability of less than 1: 20 (P<0.05).
Supplementary Investigation
The mortality and the length of hospital stay of the patients in the trial were compared with those of patients in three other medical units. One (A) was a general medical ward in a teaching hospital which carries a heavy load of acute emergencies; the second (B) was a general medical ward in the same nonteaching hospital as the trial patients ; and the third (C) was in a hospital used only for chest diseases.
Matching pairs, with the trial patients as propositi, were drawn from the hospital records of each of the three units-A, B, and C. All the patients were admitted for exacerbations of Chronic Bronchitis-Elmes et al.
bronchitis, and were matched for sex, age within five years, and date of admission within one month.
It was not possible to obtain patients to match all 56 propositi from each of the three units, but 41 were matched for unit A, 44 for unit B, and 55 for unit C. Only two facts were extracted from the notes of these patients: whether they survived the hospital admission, and, if they survived, the length of hospital stay.
Results
The trial was started in February 1963, when an emergency ward was opened for the care of acute respiratory illness. Unfortunately an insufficient number of patients were admitted to complete the trial before that winter ended. The trial was continued in the winter of 1963-4, but fewer suitable patients were available for the trial, partly because of the milder winter and partly because hospital rebuilding restricted the number of beds available (see Table I ). Assessment of the pairs at the end of the stay in hospital and at the end of the follow-up showed even less difference between treated and untreated cases. The trial was not continued long enough for any of the boundaries to be crossed. figure) giving the boundaries for " no significant difference between treatments" run from 75 pairs on the centre line to 104 pairs for the upper and lower boundaries.
Other Analyses
On admission to the trial the two groups of patients (treated and untreated) were comparable for age, sex, and sputum appearance (see Table II ). The control group had significantly better ventilatory capacity on admission than the treated patients, but had more sputum. More specimens of sputum from the control group contained H. influenzae but fewer pneumococci than the ampicillin group; these differences were not statistically significant.
Deaths.-Five patients in the control group died in spite of changing to conventional antibiotic treatment when their condition deteriorated or failed to improve (Table III) . Only one patient in the ampicillin group died. Such a difference could occur with a probability of 1: 5 and is not statistically significant. The causes of death are shown in Table IV .
Relapses in hospital were defined as occasions on which it was thought advisable to initiate additional antibiotic treatment because of persistent fever with purulent sputum either during or after the first seven days in hospital. Such episodes occurred significantly more often in the control group. After discharge there was an equal incidence of relapses requiring bed rest at home or admission to hospital (Table III) .
Other Evidence of Improvement.-Length of stay in hospital, increase in peak flow rate, fall in sputum volume, and elimination of pathogens from the sputum at the time of discharge were not significantly different in the two groups (see Table V The patients were sorted according to characteristics which might be thought to influence prognosis. It was found (Table VI) that age had no significant effect. Definite evidence of infection (grade I patients) was associated with a greater frequency of relapses. Poor ventilatory function on admission was associated with a longer stay in hospital. Neither the volume nor the purulence of the sputum during the first 24 hours was of prognostic significance. When the patients with H. influenzae in the initial sputum were compared with the other patients (Table VII) there was a difference between those receiving ampicillin and those receiving placebo. The control patients with H. influenzae had significantly more relapses in hospital and stayed in longer than the controls without H. influenzae. The ampicillin-treated patients with H. influenzae had a significantly shorter stay in hospital but the same frequency of relapses as the ampiclin-treated 
Discusion
This trial was terminated prematurely, for reasons unrelated to its results, before a statistically significant answer in the sequential analysis had been obtained. The patients in the trial were elderly and ill. Their mean age was 63 years, one-quarter were over 70 and two were over 80. Several patients had such small ventilatory capacity that they were unable to record a reading on the peak flow meter. The mortality rate of 6 deaths in 58 patients is comparable to that in two other acute medical units at the same time for similar cases. In only three of the six deaths was there any evidence that infection contributed to the cause of death.
Assessments made after seven days, when the observers were not biased by the knowledge of the bacteriological findings in the sputum, did no more than suggest that ampicillin gave some benefit compared with a placebo. Assessments made at the time of discharge and after follow-up showed even less evidence of benefit. This failure to show a statistically significant benefit after 28 pairs of patients had been studied in a sequential trial indicates the relative lack of importance of ampicillin in the hospital treatment of exacerbations of chronic bronchitis.
Ampicillin has been shown (Rolinson and Stevens, 1961) two pathogens from the sputum during treatment, though they often reappeared before the patient left hospital. However, this alteration in the flora of the bronchi appears to have conferred little additional benefit on patients already receiving routine ward treatment. This routine, with breathing exercises, postural drainage, bronchodilator sprays, and early ambulation, was applied with as much enthusiasm and frequency as was humanly possible. There was an atmosphere of active treatment for an often neglected illness which must have contributed psychologically and allowed the earlier discharge of patients.
Our results indicate that ampicillin reduces the frequency of early relapses even if it does not affect the ultimate prognosis of the acute illness. The frequency of relapses seemed to be reduced only in those patients with H. influenzae in their sputum on admission. Unfortunately this test takes time, and is especially unreliable when the patient has received antibiotics before admission. If treatment is to be started straightaway a different method of selecting which patients need antibiotic treatment is needed.
Antibiotic therapy is not without its hazards, both to the patient and to other patients around him in the hospitalenvironment. Broad-spectrum antibiotics are particularly apt to encourage cross-colonization by " hospital " antibiotic-resistant bacteria.
New methods are needed so that the patient who will really benefit from antibiotic therapy can be identified as soon as he reaches the ward. The rest of the bronchitic patients should not receive antibiotics while in hospital.
Summary
The value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis has been assessed in a double-blind trial.
Twenty-eight pairs of patients were included in a sequential trial in which all patients were treated intensively with bronchodilator drugs and physiotherapy. One member of each pair received bacteriologically effective doses of ampicillin for seven days, while the other member of the pair received placebo.
Sequential analysis of the results showed no conclusive evidence that the ampicillin was beneficial.
Ampicillin did not shorten the length of the patients' stay in hospital. In those patients whose sputum cultured Haemophilus influenzae on admission there was a reduction in the frequency of relapses while the patient was still in hospital.
There was no evidence that any such improvement caused by the ampicillin persisted after the patient was discharged from hospital.
In the decade 1952-62 125 patients were operated on for bronch~ectasis in the Southern Metropolitan Thoracic Surgical Unit, Dunedin. In 91 of these the resection was unilateral and in 34 bilateral. Two patients with unilateral disease required a second operat on for removal of a lung segment that had become bronchiectatic after the first operation. Four of those with bilateral disease required a subsequent segmental resection. In the period analysed, therefore, 165 operations for bronchiectasis were performed on 125 patients, as follows: Unilateral bronchiectasis ... 91 resections l2 subsequent resections Bilateral bronchiectasis {. 8r.e.on eecin 4 subsequent resections All these patients were referred from the Chest Clinic, Dunedin Hospital, or Regional Chest Clinics, Otago and Southland, because of failure of medical treatment.
There were 75 females and 50 males, a proportion of 1.5 to 1. This supports the experience of Ginsberg et al. (1955) . Other reported series have shown a different sex distribution (Lindskog and Hubbell, 1955) . The unilateral group comprised 53 females and 38 males, and the bilateral group 22 females and 12 males. The two groups are analysed separately.
Unilateral Bronchiectasis
Age Distribution.-The age distribution at the time of onset of symptoms and at operation is given in Table I . These figures show that in two-thirds of the patients the onset of symptoms occurred in the first decade of life. The age distribution at operat on, however, showed a different pattern. Thus over a third of the patients were operated upon in the 
